Optic Pathway Gliomas: The Trends of Basic Research to Reduce the Impact of the Disease on Visual Function

Area of Science:

• Neuro-oncology
• Ophthalmology
• Pediatric Neurology

Background:

• Pediatric optic pathway gliomas (OPGs) cause progressive, disabling visual loss.
• Current treatments (surgery, radiotherapy, chemotherapy) do not prevent or reverse vision impairment.
• Visual impairment is a major challenge in OPG management.

Purpose of the Study:

• To evaluate the potential of Nerve Growth Factor (NGF) eye drops in improving visual outcomes for OPG patients.
• To explore the mechanism of NGF in preventing retinal ganglion cell loss.

Main Methods:

• Review of existing literature on NGF eye drop instillation for OPG.
• Analysis of NGF's role in preventing caspase activation and subsequent retinal ganglion cell apoptosis.
• Assessment of clinical outcomes including visual fields, visual electric potential, and optical coherence tomography.

Main Results:

• NGF eye drops demonstrate promising results in improving visual outcomes.
• NGF appears to prevent caspase activation, reducing retinal ganglion cell loss.
• Clinical improvements observed in visual fields and OCT, but not visual acuity.

Conclusions:

• NGF eye drop administration shows potential for mitigating visual impairment in OPG.
• Further studies are warranted to elucidate the full therapeutic potential of NGF for OPG-related visual deficits.